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INTRODUCTION 
Septic shock in dogs is caused by cardiovascular and vasomotor failure associated with an 
uncontrolled intrinsic release of inflammatory mediators [1–5]. The syndrome is characterized by 
cardiovascular dysfunction, vascular permeability alterations, pulmonary oedema and tissue 
hypoxia resulting from microthrombi which may culminate in disseminated intravascular 
coagulation and catastrophic multiple organ failure [6,7]. Systemic bacterial infection, particularly 
by Gram-negative enterobacteria, haemorrhagic trauma, gastric dilation/volvulus and pancreatitis 
are the major underlying causes leading to sepsis [8,9]. Because of haemodynamic instability and 
associated hypovolemia, fluid replacement therapy is generally applied to restore effective 
circulating volume. The use of fresh frozen plasma has been recommended in cases of 
coagulopathies as it has been recognized to assist restoration of haemodynamic stability [1,5,10,11]. 
There is increasing evidence that the drivers of the haemodynamic instability are inflammatory 
mediators (particularly TNFa) activated primarily by bacterial endotoxin [3,4,12,13]. 
 
MATERIALS AND METHODS 
In this pilot study we examined the effect sera from a proprietary hyperimmune plasma product 
(Caniplas) on the activity of TNFain an in vitro L929 cell bioassay [12,14]. Two separate 
accessions of sera were provided. Initially, one hyperimmune preparation and one untreated serum 
sample were tested. On a separate occasion, three hyperimmune sera and one untreated 
sample were tested. All sera were supplied blind to the study. The effect of each serum preparation 
was tested against a dilution series of recombinant murine TNFa in a L929 cell bioassay[12,14]. 
The starting concentration of TNFa differed between the two accessions. 
 
RESULTS 
Figs. 1 (first accession) and 2 (second accession) illustrate that all sera tested exhibited antiTNFa 
activity in the in vitro bioassay. 
Secondly, it appears that hyperimmune plasma may have enhanced activity over untreated sera. 
 
DISCUSSION 
In earlier work (unpublished data) we noted that equine hyperimmune and normal sera appeared to 
exhibit antiTNFa activity in an in vitro L929 cell bioassay. This pilot study was undertaken to 
determine if a similar effect could be found in canine sera. 
There appears to be intrinsic antiTNFa activity by untreated canine serum, but this activity appears 
to be enhanced during the endotoxin vaccination regimen employed in preparing hyperimmune 
plasma. TNFa is rapidly degraded at the cellular level by neutrophil derived proteases [15] and there 
is increasing evidence that the cytokine is also modulated in the circulatory system by solubilized 
TNFa receptors [16]. Whilst this report is clearly preliminary and needs further confirmation, it 
does suggest that plasma (with hyperimmune plasma possibly having enhanced activity) may have a 
defined role in the modulation of TNFa activated inflammatory cascades characteristic of septic 
shock. 
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